Skip to main content
Premium Trial:

Request an Annual Quote

Frances Heller

Frances Heller has joined Diagnostics For All's board, effective immediately. She currently is a trustee of the Dana-Farber Cancer Institute and a board member at Zafgen and Affinivax. Heller most recently was senior vice president of business development at Bristol-Myers Squibb and was a trustee of the Bristol-Myers Squibb Foundation. Before joining Bristol-Myers Squibb, she was executive vice president of business development at Exelixis Pharmaceuticals.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.